Norvas (Amlodipine)

Amlodipine, the active ingredient in Norvas, is a calcium channel blocker presented as a tablet for oral use. It lowers blood pressure and relieves chest pain by relaxing vascular smooth muscle, and is prescribed for adults with hypertension, chronic stable angina, or coronary artery disease.

GNH USA supplies Norvas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Customers benefit from consistent product availability and regulatory support across multiple regions.

Amlodipine is used to manage cardiovascular conditions that involve elevated blood pressure or reduced coronary blood flow.

Hypertension: reduces systolic and diastolic blood pressure, decreasing the risk of stroke, myocardial infarction and heart failure. Chronic stable angina: improves myocardial oxygen supply by dilating coronary arteries, thereby relieving chest pain during exertion. Coronary artery disease: lowers cardiac workload and helps prevent ischemic events by maintaining adequate coronary perfusion.

Amlodipine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Peripheral edema: swelling of the ankles or feet, especially after prolonged standing. - Headache: mild to moderate intensity, often transient. - Flushing: sensation of warmth and redness, usually on the face or neck. - Dizziness or light‑headedness, particularly when standing quickly. - Palpitations: awareness of heartbeat irregularities. - Fatigue or general weakness.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure leading to fainting. - Myocardial infarction: rare occurrence of heart attack. - Arrhythmias: abnormal heart rhythms that may require medical attention. - Hepatic dysfunction: elevated liver enzymes or jaundice. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe skin reactions.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications.

Monitor blood pressure: measure regularly after starting or adjusting dose. Assess cardiac function: evaluate for heart failure or ischemic disease. Avoid abrupt discontinuation: taper under medical supervision to prevent rebound hypertension. Caution in hepatic impairment: consider dose adjustment or increased monitoring. Pregnancy and lactation: use only if potential benefits justify the risks. Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original container.

Amlodipine can interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): may increase plasma concentrations and risk of adverse effects. - Concurrent use with other antihypertensives: may cause excessive hypotension. - High‑dose simvastatin or other statins metabolized by CYP3A4: increased risk of myopathy.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce amlodipine effectiveness. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may exacerbate peripheral edema. - Beta‑blockers: may mask tachycardia, requiring careful heart rate monitoring.